💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, reasonably priced.
GlaxoSmithKline Pharma is scored on the pharma / healthcare framework. It keeps a fat 26.1% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.87×). Free cash flow is worth about 3.0% of its market value.
Over the last 3 years revenue compounded at 6%/yr and profit at 19%/yr. Book value has grown 9%/yr. Return on equity is an elite 61.0%. In the latest quarter profit fell 15% versus the prior quarter.
At 41× earnings, the stock sits at the 25th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~17%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 37.31 | — | — |
| P/B | 22.74 | 4.11 | worse |
| EV/EBITDA | 25.7 | 19.15 | worse |
| ROE | 60.95 | — | — |
| ROCE | 81.14 | — | — |
| ROA | 28.89 | — | — |
| Quick Ratio | 1.77 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 6% CAGR — growing but slowly. Growth is decelerating — latest year grew slower than the year before.
Profit is growing faster than revenue (19% vs 6%) — margin expansion is at work.
Operating margin has expanded from 25% to 35% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 46% — the business earns well above its cost of equity. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power. Capital efficiency improving — ROE up 11pp across the window.
19% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Low quarterly variance (8% spread) — a predictable, non-seasonal revenue stream.
Profit fell 15% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 75.0% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.